ImpediMed Limited (IPDQF) Research

ImpediMed Limited is a medical technology firm that specializes in software solutions. The company is involved in the creation, production, and global distribution of sophisticated bioimpedance spectroscopy (BIS) equipment and its accompanying software applications, serving markets in Australia, North America, and beyond. Its principal offerings include: SOZO: A non-intrusive BIS device engineered for the evaluation of lymphedema and for tracking fluid levels in individuals afflicted with heart failure. SFB7: A single-channel, tetrapolar BIS instrument utilized to assess the body composition of healthy individuals. ImpediVET: Another single-channel, tetrapolar BIS device, tailored specifically for veterinary applications to measure fluid status and tissue characteristics in animals. ImpediMed primarily markets its advanced medical devices to healthcare institutions such as hospitals and clinics. The company was founded in 1999 and its headquarters are located in Pinkenba, Australia.

Market snapshot

Symbol
IPDQF
Price
$0.01
Day change
0.00%
Market cap
$14.0M
P/E ratio
-0.50x
52-week range
0.0045-0.0514
Sector
Healthcare
Industry
Medical - Devices
Next earnings
in 2 months

Peer companies

  • Bonus BioGroup Ltd. (BBIXF)
  • Cordlife Group Limited (CLIFF)
  • Celyad Oncology S.A. (CLYYF)
  • Fluent Corp. (CNTMF)
  • Nova Eye Medical Limited (ELXMF)
  • Finch Therapeutics Group, Inc. (FNCH)
  • Marpai, Inc. (MRAI)
  • PetVivo Holdings, Inc. (PETV)

Open ImpediMed Limited (IPDQF) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.